REG - Cambridge Nutrition. - Half-year Report
23/11/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231123:nRSW3824Ua&default-theme=true
RNS Number : 3824U Cambridge Nutritional Sciences PLC 23 November 2023
CAMBRIDGE NUTRITIONAL SCIENCES PLC
("CNS" or the "Company" or the "Group")
Half-Year Report
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
Strong revenue increase, 2022 sales backlog cleared and FoodPrint® yields
significantly improved; Company firmly on track to meet market expectations
for the full year
CNS (AIM: CNSL), the specialist medical diagnostics company focused on
promoting a personalised and functional approach to health and nutrition,
announces its unaudited interim results for the six months ended 30 September
2023.
H1 Financial Highlights:
· Revenue increased 44% to £4.9m (H1 2022: £3.4m).
· Gross margin increased to 62.7% (H1 2022: 54.0%), largely due to
production efficiencies & product mix
· Adjusted EBITDA(1) £0.0m (H1 2022: restated loss £0.4m).
· Loss before tax £0.7m (H1 2022: restated loss £0.8m).
· Loss on discontinued operations £ Nil (H1 2022: restated loss of
£1.2m).
· Cash balance £4.4m (H1 2022: £2.7m).
Operational Highlights:
· Strong performance in operations with FoodPrint® yields
significantly improved.
· First USA laboratory commercialising FoodPrint®.
· MyHealth Tracker roll out expanding to all UK customers and installed
in one European country.
· Microbiome menu expansion moving into trial phase in UK.
· Creation of a continuous improvement function to build on the work
done by Chartwell Consulting.
· Appointment of new independent Non-Executive Director, Carolyn Rand.
· Successful name change to Cambridge Nutritional Sciences Plc (AIM:
CNSL), better reflecting the standalone business.
Outlook:
· Company is on track to meet market expectations for the full year.
· Healthy pipeline of sales, adding sales from three new countries with
demand expanding via our scientific educational programmes.
· MyHealth Tracker UK customer roll out expected in H2; international
roll out to commence in FY25.
· Well-funded to deliver on our strategic objectives.
· Further USA Laboratories expected to commercialise FoodPrint® in
FY25.
· The Board remains confident that the Company has a compelling case
regarding the dispute with DHSC but there have been no material developments.
The Board continues to vigorously pursue its substantial counterclaim for
losses incurred.
(1)Adjusted for exceptional items, amortisation of intangible assets and share
based payment charges.
Commenting on the results, Jag Grewal, Chief Executive officer, said:
"The first half of this year delivered encouraging performance in both
financial and operational terms. It is particularly reassuring to see
improvements in the operational side of the business yielding tangible
results. We continue to build a new foundation as a standalone business and
believe we have the right strategy and vision to build on a leadership
position in the exciting market of personalised health and nutrition."
Investor presentation
Simon Douglas, Chair, and Jag Grewal, CEO, will provide a live presentation
relating to the Interim Results via the Investor Meet Company platform today
at 4:30pm GMT. The presentation is open to all existing and potential
shareholders.
Investors can sign up to Investor Meet Company for free and add to
meet Cambridge Nutritional Sciences PLC via:
https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor
(https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor)
The investor presentation will be available later this morning on the Company
website:
https://www.cnsplc.com/financials/presentations
(https://www.cnsplc.com/financials/presentations)
The information communicated in this announcement is inside information for
the purposes of Article 7 of EU Regulation 596/2014
Contacts:
Cambridge Nutritional Sciences PLC www.cnsplc.com (http://www.cnsplc.com)
Jag Grewal, Chief Executive via Walbrook PR
Cavendish Capital Markets Limited Tel: 020 7220 0500
Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus / Charlotte Edgar Mob: 07980 541 893 / Mob: 07884 664 686/
Sam Allen Mob: 07502 558 258
About Cambridge Nutritional Sciences plc
Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical
diagnostics company focused on industry-leading Health and Nutrition products.
Chair's Statement
Overview
I am pleased to report that we have made a positive start over the first half
of this fiscal year. The production challenges previously reported have been
overcome and we have now cleared the sales backlog. We are delivering on our
strategic objectives and have now established ourselves as a standalone
business focused on Health and Nutrition under our new name of Cambridge
Nutritional Sciences Plc ('CNS'). The market we serve remains exciting with a
significant opportunity for global growth as more people are aware of their
personalised health and its link to nutrition.
Financial Performance
Revenue increased 44.0% to £4.9m (H1: £3.4m) helped by both production and
yield improvements of FoodPrint® enabling the clearing of the sales backlog
arising from the FY23 production issues. FY24 revenue is expected to be in
line with expectations.
Revenue by product group:
§ Sales of FoodPrint® increased 47.0% to £3.3m (H1 2022: £2.2m)
§ Sales of Food Detective® were £0.7m in line with the prior year
§ CNS Lab and other sales were up 97.0% to £0.9m (H1 2022: £0.4m)
Gross profit from operations increased to £3.1m (H1 2022: £1.9m) with an
improved gross margin percentage of 62.7% (H1 2022: 54.0%). The increase in
margin principally reflects the improvements in production yields as well as a
higher proportion of high margin FoodPrint® tests in the product mix. The
Board is confident that Food Print® margins will continue at this improved
level in H2 FY24 as the Company benefits from the enhanced operational
efficiencies.
Overheads increased by 31% to £3.5m (H1 2022: restated £2.7m). £0.3m from
underlying period growth with the balance related to one-time investment of
the operational improvement project and business realignment, and a £0.1m FX
headwind.
The Group continues to consider EBITDA and adjusted EBITDA (adjusted for
exceptional items and share-based payments) as being the appropriate measures
of profitability being aligned with the cash generating activities of the
business. The adjusted EBITDA was £0.0m (H1 2022: loss of £0.2m). The £0.3m
adjustment for exceptional items is related to realigning the group for the
future.
The cash balance on 30 September 2023 was £4.4m (H1 2022: £2.7m, 31 March
2023: £5.1m).
Operational Update
Earlier in the year we were pleased to report that the production challenges
announced have been resolved, after working with industry specialists,
Chartwell Consulting ('Chartwell') over the six-month period to embed new
working processes. The result is that FoodPrint® production yields have
increased and are significantly higher than the preceding six months,
demonstrating the effectiveness of the improved measures. These newly
implemented measures, alongside management changes, have allowed us to address
the order backlog and the market's demand for food sensitivity tests remains
strong. As part of this process, and in our drive to constantly seek
operational improvements, we now have a permanent continuous improvement
function in our operations department to promote further efficiency and
productivity across the business. Historically the business support systems
were delivered from the group in Scotland, and we are now in the final steps
post separating the business. Operationally we continue to evaluate
alternative technologies for our flagship product, FoodPrint®, to ensure the
long-term future of the product.
Strategic Priorities
The MyHealthTracker App ('the App'), announced in March 2023, is designed for
use on both iOS and Android platforms and will give us a direct connection to
customers. It has been rolled out across the UK with selected health care
professionals and their customers and initial feedback shows that the product
has been well received by both groups. We are looking to release the product
more broadly in the UK in early 2024. During the period we also supported
initial installation of the digital platform in one European country, and we
look forward to introducing the App into more geographies during 2024 and
beyond.
As we announced at the beginning of 2023, FoodPrint® was installed in our
first laboratory in the USA and following approvals is now live and actively
commercialising FoodPrint®. Further expansion into the USA is planned, with
validation and approvals currently taking place with two other laboratories in
the region.
We saw robust growth in our UK market, which is serviced by our own testing
laboratory, CNSLab. Sales grew by 97%, driven by both practitioner-based
business as well as direct consumer demand serviced by our white-label
partners.
Our menu expansion into Microbiome testing is progressing with a UK based
trial in conjunction with a test report provider which will allow us to assess
the market feedback and requirements to further define the product offering in
what is a fast-evolving area.
Dispute with the DHSC
There is no further progress to report in our dispute with the Department of
Health and Social Care ('DHSC'). The Board continues to vigorously pursue its
substantial counterclaim for losses incurred towards the DHSC, as a direct
result of its failure to licence the necessary intellectual property to permit
the contract to move forward and their failure to notify the Group of their
inability to do so in a timely manner. The Board remains confident that the
Company has a compelling case.
Current Trading and Outlook
We are pleased with progress over the first half of the fiscal year as the
Company builds a solid foundation from which it can continue to grow. H2 is
expected to remain strong, although in the absence of any further backlog to
fulfill, is expected to be slightly lower than H1 FY24 with the full year's
revenue expected to be in line with market expectations. The investment for
the final steps in the separation of the business from the historical group
will be completed during FY25. We will continue with our plans of expanding
into the USA market and adding value to the customer base with two other
laboratories in the region working on the validation and approval of the
FoodPrint test in readiness for launch in early FY25. The MyHealth Tracker
roll out in the UK will be finalised in Q4 FY24 and a further phased roll out
is planned for FY25.
The Board's expectations are that the market conditions remain good and that
we are well capitalised and in a strong position to grow as a standalone
business.
Simon Douglas
Non-Executive Chair
Consolidated Statement of Comprehensive Income
for the six months ended 30 September 2023
As restated*
6 months ended. 6 months ended. 12 months ended.
30 September 2023 30 September 2022 31 March 2023
Note £'000 £'000 £'000
Continuing operations
Revenue 3 4,934 3,434 7,546
Cost of sales (1,841) (1,581) (4,001)
Gross profit 3,093 1,853 3,545
Administration costs (2,746) (1,959) (4,755)
Selling and marketing costs (790) (730) (1,530)
Other income 51 - 25
Operating loss before exceptional items (392) (836) (2,715)
Exceptional items (294) - (524)
Operating loss after exceptional items (686) (836) (3,239)
Finance costs 4 (12) (6) (13)
Loss before taxation (698) (842) (3,252)
Tax credit 5 - - 80
Loss for the period from continuing operations (698) (842) (3,172)
Discontinued operations
Loss after tax for the period from discontinued operations 6 - (1,245) (688)
Loss for the period (698) (2,087) (3,860)
Other comprehensive (losses)/income to be reclassified to profit and loss in
subsequent periods
Exchange differences on translation of foreign operations (3) 22 (15)
Other comprehensive income for the period (3) 22 (15)
Total comprehensive losses (701) (2,065)
for the period
(3,875)
Earnings per share (EPS)
Basic and diluted EPS on loss for the period 7 (0.3)p (0.9)p (1.7)p
Earnings per share for continuing operations
Basic and diluted EPS on loss for the period from continuing operations 7 (0.3)p (0.4)p (1.4)p
* See note 2 for details regarding the restatement.
Consolidated Balance Sheet
as at 30 September 2023
30 September 2023 30 September 2022 31 March 2023
Note £'000 £'000 £'000
ASSETS
Non-current assets
Intangibles 8 4,313 4,556 4,525
Property, plant, and equipment 9 515 1,062 567
Right of use assets 9 177 62 21
Deferred taxation 994 1,120 997
Total non-current assets 5,999 6,800 6,110
Current assets
Inventories 1,073 1,074 777
Trade and other receivables 2,290 6,544 2,403
Cash and cash equivalents 4,396 2,712 5,115
Total current assets 7,759 10,330 8,295
Assets held for sale - - -
Total assets 13,758 17,130 14,405
EQUITY AND LIABILITIES
Equity
Share capital 10,244 10,244 10,244
Share premium 25,072 25,100 25,072
Retained deficit (25,974) (23,534) (25,319)
Translation reserve (49) (8) (46)
Total equity 9,293 11,802 9,951
Liabilities
Non-current liabilities
Long-term borrowings 3 35 19
Lease liabilities 77 - -
Deferred income 2,500 2,500 2,500
Total non-current liabilities 2,580 2,535 2,519
Current liabilities
Short-term borrowings 33 31 32
Lease liabilities 101 69 23
Trade and other payables 1,452 2,282 1,525
Total current liabilities 1,586 2,382 1,580
Liabilities directly associated with assets held for sale 299 411 355
Total liabilities 4,465 5,328 4,454
Total equity and liabilities 13,758 17,130 14,405
* See note 2 for details regarding the restatement.
Consolidated Statement of Changes in Equity
for the six months ended 30 September 2023
Share Share Retained Translation
capital premium deficit reserve Total
£'000 £'000 £'000 £'000 £'000
Balance at 31 March 2022 8,044 25,340 (21,537) (31) 11,816
Loss for the period to 30 September 2022 - - (2,087) - (2,087)
Other comprehensive losses - net exchange adjustments - - - 23 23
Total comprehensive (losses)/income for the period - - (2,087) 23 (2,064)
Issue of share capital for cash consideration 2,200 - - - 2,200
Expenses in connection with share issue - (240) - - (240)
Share-based payments - - 90 - 90
Balance at 30 September 2022 10,244 25,100 (23,534) (8) 11,802
Loss for the period to 31 March 2023 - - (1,773) - (1,773)
Other comprehensive income - net exchange adjustments - - - (38) (38)
Total comprehensive losses for the period - - (1,773) (38) (1,811)
Expenses in connection with share issue - (28) - - (28)
Share-based payments - - (12) - (12)
Balance at 31 March 2023 10,244 25,072 (25,319) (46) 9,951
Loss for the period to 30 September 2023 - - (698) - (698)
Other comprehensive income - net exchange adjustments - - - (3) (3)
Total comprehensive (losses)/income for the period - - (698) (3) (701)
Share-based payments - - 43 - 43
Balance at 30 September 2023 10,244 25,072 (25,974) (49) 9,293
* See note 2 for details regarding the restatement.
Consolidated Cash Flow Statement
for the six months ended 30 September 2023
As restated*
6 months ended 6 months ended 12 months ended
30 September 2023 30 September 2022 31 March 2023
£'000 £'000 £'000
Cash flows generated from operations
Loss for the year from continuing operations (698) (842) (3,172)
Loss for the year from discontinued operations - (1,245) (688)
Adjustments for:
Depreciation 108 120 219
Amortisation of intangible assets 219 225 372
Impairment and derecognition of intangible assets - 15 15
Impairment of assets related to aborted Ely relocation - - 399
Impairment loss recognised on the remeasurement to fair value - 176 176
Share-based payments 43 90 78
Taxation - - (380)
Finance costs 12 21 16
Cash outflow from operating activities before working capital movement (316) (1,440) (2,965)
Decrease in trade and other receivables 113 672 812
(Increase)/decrease in inventories (296) (168) 128
Decrease in trade and other payables (73) (843) (1,466)
Movement in grants - (4) (139)
Taxation received - - 478
Cash outflow from operating activities (572) (1,783) (3,152)
Investing activities
Finance income - - 19
Income from sale of CD4 business - 1,315 5,315
Purchase of property, plant, and equipment (10) (25) (25)
Purchase of intangible assets (7) (51) (128)
Net cash (outflow)/inflow in investing activities (17) 1,239 5,181
Financing activities
Finance costs (1) - (1)
Proceeds from issue of share capital - 2,200 2,200
Expenses in connection with share issue - (240) (268)
Principal portion of asset finance payments (71) (243) (314)
Interest portion of asset finance payments (7) (16) (25)
Principal portion of lease liability payments (47) (46) (97)
Interest portion of lease liability payments (4) (5) (9)
Net cash (outflow)/inflow from financing activities (130) 1,650 1,486
Net (decrease)/increase in cash and cash equivalents (719) 1,106 3,515
Effects of exchange rate movements - 1 (5)
Cash and cash equivalents at beginning of period 5,115 1,605 1,605
Cash and cash equivalents at end of the period 4,396 2,712 5,115
* See note 2 for details regarding the restatement.
Notes to the Interim Report
for the six months ended 30 September 2023
1. BASIS OF PREPARATION
For the purpose of preparing the 31 March 2023 annual financial statements the
Directors used IFRS as adopted by the EU and in accordance with the AIM Rules
issued by the London Stock Exchange. In preparing these interim financial
statements, the accounting policies used in the Group's Annual Report for the
year ended 31 March 2023 have been applied consistently. The Group has not
applied IAS 34 Interim Financial Reporting, which is not mandatory for AIM
companies, in the preparation of these interim financial statements.
The interim financial statements are unaudited. The information shown in the
consolidated balance sheet as at 30 September 2023 does not constitute
statutory accounts as defined in Section 435 of the Companies Act 2006 and the
information in respect of the year ended 31 March 2023 has been extracted from
the Group's 2023 Annual Report which has been filed with the Registrar of
Companies. The report of the auditors on the financial statements contained
within the Group's 2023 Annual Report was unqualified and did not contain a
statement under sections 498 (2) and 498 (3) of Chapter 3, Part 16 of the
Companies Act 2006. These interim financial statements were approved by the
Board of Directors on 22 November 2023.
2. RESTATEMENT OF COMPARATIVES
Group
Discontinued operations
Following a review of administration costs, £186,000 of credits applicable to
discontinued operations have been identified as being incorrectly applied to
continuing operations as reported in the interim results reported for the six
months ended 31 September 2022. This does not affect the results reported in
the annual report for the year to 31 March 2023.
The effect of the restatements noted above on the consolidated statement of
comprehensive income as at 30 September 2022 is as follows:
As reported Restatement As restated
30 September 2022 30 September 2022 30 September 2022
£'000 £'000 £'000
Continuing operations
Revenue 3,434 - 3,434
Cost of sales (1,581) - (1,581)
Gross profit 1,853 - 1,853
Administration costs (1,773) (186) (1,959)
Selling and marketing costs (730) - (730)
Other income - - -
Operating loss before exceptional items (650) (186) (836)
Exceptional items - - -
Operating loss after exceptional items (650) (186) (836)
Finance costs (6) - (6)
Loss before taxation (656) (186) (842)
Tax credit/(expense) - - -
Loss for the period from continuing operations (656) (186) (842)
Discontinued operations
Loss after tax for the period from discontinued operations (1,431) 186 (1,245)
Loss for the period (2,087) - (2,087)
Other comprehensive income to be reclassified to profit and loss in subsequent
periods
Exchange differences on translation of foreign operations 22 - 22
Other comprehensive income for the period 22 - 22
Total comprehensive losses for the period (2,065) - (2,065)
Earnings per share (EPS)
Basic and diluted EPS on loss for the period (0.3)p - (0.3)p
Earnings per share for continuing operations
Basic and diluted EPS on loss for the period from continuing operations (0.3)p (0.1)p (0.4)p
3. SEGMENT INFORMATION
Following the withdrawal from COVID-19 products and the decision taken in
March 2022 to dispose of the CD4 business, the sale of which was completed on
31 July 2022, the only remaining division is Health and Nutrition. The Global
Health division specialised in the research, development, production, and
marketing of kits to aid the diagnosis of infectious diseases, including
COVID-19.
The Health and Nutrition division specialises in the research, development,
and production of kits to aid the detection of immune reactions to food. It
also provides clinical analysis to the general public, clinics, and health
professionals.
The Corporate segment consists of centralised corporate costs which are not
allocated to the trading activities of the Group.
Inter segment transfers or transactions are entered into under the normal
commercial conditions that would be available to unrelated third parties.
Business segment information
Health and
Nutrition Corporate Total
6 months to 30 September 2023 £'000 £'000 £'000
Revenue 5,062 - 5,062
Inter-segment revenue (128) - (128)
Total revenue 4,934 - 4,934
Cost of sales (1,841) - (1,841)
Gross profit 3,093 - 3,093
Operating costs (2,739) (746) (3,485)
Operating profit/(loss) before exceptional items 354 (746) (392)
Exceptional items (151) (143) (294)
Operating profit/(loss) after exceptional items 203 (889) (686)
Depreciation 108 - 108
Amortisation 219 - 219
EBITDA 530 (889) (359)
Exceptional items 151 143 294
Share-based payment charges - 17 17
Adjusted EBITDA 681 (729) (48)
Share-based payment charges - (17) (17)
Depreciation (108) - (108)
Amortisation (219) - (219)
Net finance costs (12) - (12)
Exceptional costs (151) (143) (294)
Profit/(loss) before tax 191 (889) (698)
Exceptional items 151 143 294
Share-based payment charges - 17 17
Amortisation 61 - 61
Adjusted profit/(loss) before tax 403 (729) (326)
3. SEGMENT INFORMATION (CONTINUED)
As restated*
Health and As restated*
Nutrition Corporate Total
6 months to 30 September 2022 £'000 £'000 £'000
Revenue 3,533 - 3,533
Inter-segment revenue (99) - (99)
Total revenue 3,434 - 3,434
Cost of sales (1,581) - (1,581)
Gross profit 1,853 - 1,853
Operating costs (2,133) (556) (2,689)
Operating loss before exceptional items (280) (556) (836)
Exceptional items - - -
Operating loss after exceptional items (280) (556) (836)
Depreciation 106 - 106
Amortisation 225 - 225
EBITDA 51 (556) (505)
Share-based payment charges - 90 90
Adjusted EBITDA 51 (466) (415)
Share-based payment charges - (90) (90)
Depreciation (106) - (106)
Amortisation (225) - (225)
Net finance costs (6) - (6)
Loss before tax (286) (556) (842)
Share-based payment charges - 90 90
Amortisation 49 - 49
Adjusted loss before tax (237) (466) (703)
* See note 2 for details regarding the restatement.
The adjusted profit/(loss) before taxation is a key measure of the Group's
trading performance used by the Directors. The reported numbers are non-GAAP
measures
3. SEGMENT INFORMATION (CONTINUED)
6 months to 6 months to
30 September 2023 30 September 2022
£'000 £'000
Revenues
UK 830 423
Rest of Europe 1,167 1,125
North America 1,031 606
South/Central America 243 141
India 282 286
Asia 874 651
Africa and the Middle East 507 202
4,934 3,434
6 months to 6 months to inc/(dec)
30 September 2023 30 September 2022
£'000 £'000 %
FoodPrint® 3,284 2,239 47%
Food Detective® 732 706 4%
CNS laboratory service 829 420 97%
Food ELISA/other 89 69 28%
4,934 3,434 44%
4. FINANCE COSTS
6 months to 6 months to
30 September 2023 30 September 2022
Continuing operations £'000 £'000
Interest payable on bank overdraft 1 -
Interest payable on lease liabilities 4 4
Interest on hire purchase and asset finance arrangements 7 2
12 6
5. TAXATION
6 months to 6 months to
30 September 2023 30 September 2022
Continuing operations £'000 £'000
Tax credited in the income statement
Current tax - current year - -
Current tax - prior year adjustment - -
Deferred tax - current year - -
Deferred tax - prior year adjustment - -
- -
Reconciliation of total tax credit
Factors affecting the tax credit for the period: £'000 £'000
Loss taxable (672) (656)
Effective rate of taxation 19% 19%
Loss before tax multiplied by the effective rate of tax (128) (125)
Effects of:
Deferred tax asset not recognised 128 125
Tax credit for the period - -
6. DISCONTINUED OPERATIONS
As restated*
6 months to
30 September 2022
£'000
Revenue 657
Cost of sales (567)
Gross profit/(loss) 90
Administration costs (1,175)
Selling and marketing costs -
Other income 4
Operating loss before exceptional items (1,081)
Exceptional items -
Operating loss after exceptional items (1,081)
Finance costs (15)
Impairment loss recognised on the remeasurement to fair value less costs to (149)
sell
Loss before taxation (1,245)
Tax -
Loss for the period from discontinued activities (1,245)
* See note 2 for details regarding the restatement.
Adjusted loss before taxation
6 months to
30 September 2022
£'000
Loss for the period from discontinued activities (1,245)
Exceptional items -
Amortisation of intangible assets 7
Adjusted loss for the period from discontinued activities (1,238)
Earnings per share
6 months to
30 September 2022
£'000
Basic, loss for the period from discontinued operations (0.5)p
Diluted, loss for the period from discontinued operations (0.5)p
Adjusted, loss for the period from discontinued operations (0.5)p
6. DISCONTINUED OPERATIONS (CONTINUED)
The major classes of assets and liabilities of the Global Health business as
at 30 September 2023 are, as follows:
30 September 2023 30 September 2022
£'000 £'000
Assets
Property, plant, and equipment - -
Total assets held for sale - -
Liabilities
Borrowings (299) (411)
Total liabilities directly associated with the assets held for sale (299) (411)
Net liabilities directly associated with the disposal group (299) (411)
The property, plant and equipment relate primarily to COVID-19 plant and
equipment no longer used in the business which have all been written down to
zero value, the liabilities relate to the hire purchase on these assets.
7. EARNINGS PER SHARE
As restated*
6 months to 6 months to
30 September 2023 30 September 2022
£'000 £'000
Loss attributable to equity holders of the Group
Continuing operations (698) (842)
Discontinued operations - (1,245)
Loss attributable to equity holders of the Group for basic earnings (698) (2,087)
2023 2022
Continuing operations Number Number
Weighted average number of shares 237,685,180 225,443,711
Share options - -
Diluted weighted average number of shares 237,685,180 225,443,711
* See note 2 for details regarding the restatement.
The number of shares in issue at the period end was 237,685,180. Basic
earnings per share are calculated by dividing profit for the year attributable
to ordinary equity holders of the Group by the weighted average number of
ordinary shares outstanding during the year.
Diluted earnings per share are calculated by dividing the loss attributable to
ordinary equity holders of the Group by the weighted average number of
ordinary shares outstanding during the year plus the weighted average number
of ordinary shares that would be issued on the conversion of all the dilutive
potential ordinary shares into ordinary shares. Diluting events are excluded
from the calculation when the average market price of ordinary shares is lower
than the exercise price.
Adjusted earnings per share on loss for the period
The Group presents adjusted earnings per share which is calculated by taking
adjusted loss before taxation and adding the tax credit in order to allow
shareholders to understand better the elements of financial performance in the
year, so as to facilitate comparison with prior periods and to assess better
trends in financial performance.
6 months to 6 months to
30 September 2023 30 September 2022
£'000 £'000
Loss attributable to equity holders of the Group (698) (2,087)
Exceptional items 294 -
Amortisation of intangible assets 61 56
Share-based payment charges 17 90
Adjusted loss attributable to equity holders of the Group (326) (1,941)
Adjusted loss for the year - continuing operations
The reported numbers are non-GAAP measure
6 months to 6 months to
30 September 2023 30 September 2022
£'000 £'000
(Loss)/profit for the period from continuing operations (698) (842)
Exceptional items 294 -
Amortisation of intangible assets 61 49
Share-based payment charges 17 90
Adjusted (loss)/profit for the period from continuing operations (326) (703)
* See note 2 for details regarding the restatement.
7. EARNINGS PER SHARE (CONTINUED)
Adjusted EPS on loss for the period (0.1)p (0.8)p
Adjusted EPS on loss for the period from continuing operations (0.1)p (0.3)p
Adjusted loss before taxation, which is a key measure of the Group's trading
performance used by the Directors, is derived by taking statutory loss before
taxation and adding back exceptional items, amortisation of intangible assets
(excluding development costs) and share-based payment charges.
8. INTANGIBLES
Licences/ Technology Customer Development
Goodwill software assets relationships costs Total
£'000 £'000 £'000 £'000 £'000 £'000
Cost
At 31 March 2022 3,017 1,634 1,975 100 9,181 15,907
Additions - - - - 16 16
Additions - internally generated - - - - 35 35
At 30 September 2022 3,017 1,634 1,975 100 9,232 15,958
Additions - 50 - - 50 100
Additions - internally generated - - - - (23) (23)
Reallocated from property, plant, and equipment - 42 - - - 42
At 31 March 2023 3,017 1,726 1,975 100 9,259 16,077
Additions - 7 - - - 7
At 30 September 2023 3,017 1,733 1,975 100 9,259 16,084
Accumulated amortisation
At 31 March 2022 - 1,619 1,440 100 8,003 11,162
Amortisation charge in the period - - 49 - 176 225
Impairment charge - 15 - - - 15
At 30 September 2022 - 1,634 1,489 100 8,179 11,402
Amortisation charge in the period - 10 50 - 87 147
Reallocated from property, plant, and equipment - 4 - - - 4
Currency translation - (1) - - - (1)
At 31 March 2023 - 1,647 1,539 100 8,266 11,552
Amortisation charge in the period - 12 49 - 158 219
At 30 September 2023 - 1,659 1,588 100 8,424 11,771
Net book value
At 30 September 2023 3,017 74 387 - 835 4,313
At 31 March 2023 3,017 79 436 - 993 4,525
At 30 September 2022 3,017 - 486 - 1,053 4,556
9. FIXED ASSETS
Right of use Leasehold Plant and
assets improvements machinery Total
Consolidated £'000 £'000 £'000 £'000
Cost
At 31 March 2022 412 696 2,461 3,569
Additions - 1 24 25
Currency translation - - 1 1
At 30 September 2022 412 697 2,486 3,595
Additions - (1) 1 -
Reallocated to intangible assets - - (42) (42)
At 31 March 2023 412 696 2,445 3,553
Additions 202 - 10 212
Disposals (412) - - (412)
At 30 September 2023 202 696 2,455 3,353
Accumulated depreciation
At 31 March 2022 306 484 1,535 2,325
Charge in the period 44 - 76 120
Impairment to fair value - - 27 27
Currency translation - (1) - (1)
At 30 September 2022 350 483 1,638 2,471
Charge in the period 41 - 58 99
Impairment to fair value - 210 189 399
Reallocated to intangible assets - - (4) (4)
Currency translation - 1 (1) -
At 31 March 2023 391 694 1,880 2,965
Charge in the period 46 - 62 108
Disposals (412) - - (412)
At 30 September 2023 26 694 1,942 2,662
Net book value
At 30 September 2023 177 2 513 692
At 31 March 2023 21 2 565 588
At 30 September 2022 62 214 848 1,124
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR BRBDBIXDDGXDRecent news on Cambridge Nutritional Sciences
See all newsREG - Cambridge Nutrition. - Grant of Options
AnnouncementREG - Cambridge Nutrition. - Appointment of Chief Executive Officer
AnnouncementREG - Cambridge Nutrition. - Holding(s) in Company
AnnouncementREG - Cambridge Nutrition. - Omega Diagnostics Summons Update
AnnouncementREG - Cambridge Nutrition. - Holding(s) in Company
Announcement